| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
PEGs
PROTAC Linkers. |
|---|---|
| ln Vitro |
As a linker molecule, Propargyl-PEG2-CH2COOH itself has no intrinsic biological activity; it serves as a structural connector to join a target protein ligand and an E3 ubiquitin ligase ligand in PROTAC synthesis. The terminal alkyne group is a click chemistry handle that can undergo CuAAc with azide-containing molecules to form a stable triazole linkage. This reaction is highly specific and can be performed under mild conditions. The carboxylic acid can be activated with EDC and NHS to form an amide bond with primary amine-containing ligands. The orthogonal functional groups (alkyne and carboxylic acid) enable stepwise conjugation to two different ligands. The PEG2 spacer provides a short, hydrophilic, and flexible connection, which can facilitate the formation of productive ternary complexes.
|
| ln Vivo |
No specific in vivo activity has been reported for this linker alone; its activity is derived from the final PROTAC molecule after conjugation with appropriate ligands. The in vivo efficacy of a complete PROTAC is determined in animal models.
|
| Enzyme Assay |
N/A; this compound is not assessed in isolated enzyme/receptor binding assays. As a synthetic intermediate, its quality is typically confirmed by analytical methods such as HPLC and NMR, with a standard purity of ≥95%. The alkyne group can be characterized by its characteristic IR absorption at around 2100-2260 cm-1. The terminal alkyne proton in 1H NMR typically appears as a triplet around 2.4-2.5 ppm (J ≈ 2.5 Hz) or a singlet around 2.0-3.0 ppm depending on the substitution pattern. The IUPAC name is 2-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy)acetic acid.
|
| Cell Assay |
N/A; this linker is not tested alone in cell-based assays. It is used as a building block for constructing PROTACs. In a typical synthesis, the alkyne group is reacted with an azide-containing ligand via CuAAc using CuSO4 and sodium ascorbate as catalyst in a THF/water mixture. The carboxylic acid is activated with EDC and NHS and reacted with a primary amine-containing ligand to form an amide bond. The resulting PROTAC is then tested in cells for target degradation activity. The PEG2 spacer is short and may be optimal for PROTACs targeting proteins with closely spaced binding sites.
|
| Animal Protocol |
N/A; no animal studies are performed with the linker alone. For a complete PROTAC conjugate, in vivo studies are conducted following institutional guidelines. The compound is typically formulated using a vehicle containing DMSO, PEG300, Tween-80, and saline and administered via intraperitoneal (IP) or intravenous (IV) injection. The PEG2 spacer may improve the pharmacokinetic properties of the conjugate by enhancing water solubility.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of 202.20, a molecular formula of C9H14O5, and a standard purity of ≥95%. The IUPAC name is 2-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy)acetic acid. It appears as a solid or colorless liquid. For storage, it should be kept at 4degC, stored under nitrogen, sealed, away from moisture. It is soluble in DMSO and other organic solvents. The product should be protected from light. SMILES: C(COCCOCC#C)OCC(O)=O. CAS: 944561-46-0.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not for human therapeutic or clinical applications. Standard chemical safety precautions should be observed during handling. The alkyne group should be handled with care to avoid premature reactions. The product should be stored away from oxidizing agents. It is not an approved drug and has not been cleared for clinical use. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.
|
| References |
[1]. Guangrong Zheng, et al. Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof. WO2017184995A1.
|
| Additional Infomation |
The short PEG2 spacer combined with a terminal alkyne and a carboxylic acid provides a minimalistic linker for constructing PROTACs. This linker is ideal for target-E3 ligase pairs that require a short, rigid connection for optimal ternary complex formation. The terminal alkyne enables CuAAc click chemistry with azide-functionalized ligands, providing a versatile conjugation strategy. The short PEG2 spacer may also be used as a building block for constructing longer linkers via iterative click chemistry or other coupling reactions. This compound is a valuable tool for studying structure-activity relationships in PROTAC design.
|
| Molecular Formula |
C9H14O5
|
|---|---|
| Molecular Weight |
202.20
|
| Exact Mass |
202.084
|
| CAS # |
944561-46-0
|
| PubChem CID |
58281034
|
| Appearance |
Colorless to light yellow liquid（Density：1.158±0.06 g/cm3）
|
| Density |
1.158±0.06 g/cm3(Predicted)
|
| Boiling Point |
334.9±27.0 °C(Predicted)
|
| Flash Point |
129.8±17.2 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.466
|
| LogP |
-0.83
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
14
|
| Complexity |
193
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C#CCOCCOCCOCC(=O)O
|
| InChi Key |
FWONAGPFSKACQC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H14O5/c1-2-3-12-4-5-13-6-7-14-8-9(10)11/h1H,3-8H2,(H,10,11)
|
| Chemical Name |
2-[2-(2-prop-2-ynoxyethoxy)ethoxy]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9456 mL | 24.7280 mL | 49.4560 mL | |
| 5 mM | 0.9891 mL | 4.9456 mL | 9.8912 mL | |
| 10 mM | 0.4946 mL | 2.4728 mL | 4.9456 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
